Affimed GmbH

80 articles with Affimed GmbH

• 

  Affimed Joins Forces with Roivant in Fight Against Cancer

  11/10/2020

  Affimed receives $60 million up front with potential for up to $2 billion more in partnership deal with Roivant Sciences.
• 

  10 Immuno-Oncology Deals Worth Talking About

  3/26/2019

  Immuno-oncology has become a key lynchpin in the pipelines of many pharmaceutical companies. The global cancer immunotherapy market is expected to more than double over the next eight years to $126.9 billion by 2026.
• 

  Patient Death and Life-Threatening Side Effects Cause Affimed to Hold Phase I Cancer Trials

  10/9/2018

  Affimed, based in Heidelberg, Germany, placed a clinical hold on its two AFM11 Phase I clinical trials. AFM11 is being evaluated in the trials for relapsed or refractory CD19 positive B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia.

• GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration

  8/29/2018

  GT Biopharma Inc. is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary NK-engager and Bispecific Antibody Drug Conjugate platforms.

• 

  Affimed Stock More Than Doubles After $4.9 Billion Deal with Roche

  8/28/2018

  Heidelberg, Germany-based Affimed NV inked a licensing deal with Switzerland-based Roche for $96 million upfront, but that was only a fraction of the entire deal. Affimed shares rocketed, more than doubling to hit $148.07.

• Affimed Announces Closing of Public Offering of Common Stock and Exercise of Underwriters' Option to Purchase Additional Shares

  2/16/2018

  Jefferies LLC and Wells Fargo Securities, LLC are acting as joint book-running managers.

• Affimed Announces Proposed Public Offering of Common Stock

  2/13/2018

  All of the shares in the offering will be sold by Affimed.

• Affimed Announces Pricing of Public Offering of Common Stock

  2/13/2018

  The offering is expected to close on or about February 15, 2018, subject to customary closing conditions.

• Affimed Reports New Data for AFM13 From Two Separate Clinical Trials in Hodgkin and CD30-Positive Lymphomas

  2/1/2018

  The data demonstrate that AFM13 was well-tolerated and showed promising therapeutic efficacy both in combination with the anti-PD-1 antibody Keytruda in Hodgkin lymphoma and as monotherapy in CD30-positive lymphoma.

• Affimed Appoints Dr. Wolfgang Fischer As Chief Operating Officer

  9/13/2017

• Affimed Reports Financial Results For Second Quarter 2017

  8/1/2017

• Affimed Presents Data On First-In-Class BCMA-Targeting Immune Cell Engager AFM26 At ASCO Annual Meeting 2017

  6/6/2017

• Affimed Announces Annual General Meeting Of Shareholders

  5/22/2017

• Affimed Reports Financial Results For First Quarter 2017

  5/17/2017

• Affimed Announces First Quarter 2017 Financial Results And Corporate Update Conference Call

  5/10/2017

• Affimed Release: Biopharma Announces Proposed Public Offering Of Common Stock

  1/20/2017

• Affimed Release: Biopharma Provides Update On NK-Cell Immuno-Oncology Platform

  1/11/2017

• Affimed To Present At Upcoming Investor Conferences

  9/1/2016

• Affimed Announces Annual General Meeting Of Shareholders

  5/24/2016

• Affimed To Present At The UBS Global Healthcare Conference -- New York

  5/17/2016